Vericel Announces FDA Approval and Commercial Availability of MACI Arthro

Core Insights - The FDA has approved Vericel Corporation's MACI® for arthroscopic delivery, targeting the $3 billion addressable market for cartilage repair [1][2] - MACI Arthro offers a less invasive technique for repairing knee cartilage defects, potentially increasing market penetration and revenue growth for the company [2][3] Company Overview - Vericel Corporation specializes in advanced therapies for sports medicine and severe burn care, with a focus on innovative cell therapies and specialty biologics [6] - The company markets three main products: MACI, Epicel®, and holds rights to NexoBrid® [6] Product Details - MACI is the first FDA-approved cellularized scaffold product for repairing full-thickness cartilage defects in the knee, utilizing the patient's own cartilage cells [2][3] - The new MACI Arthro technique allows for treatment of defects up to 4 cm², specifically targeting the most common defects in the market [2][3] Market Potential - The MACI addressable market includes approximately 20,000 patients annually, representing one-third of the total market [2] - The company plans to expand its target surgeon base from 5,000 to 7,000, focusing on those performing high volumes of cartilage repair surgeries [2]